Rigel Pharmaceuticals (RIGL) Enterprise Value (2010 - 2026)

Rigel Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$146.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 90.25% year-over-year to -$146.7 million; the TTM figure through Mar 2026 stood at -$146.7 million (down 90.25% YoY), while the FY2025 annual figure was -$155.0 million, down 100.4% from the prior year.
• Enterprise Value was -$146.7 million for Q1 2026 at Rigel Pharmaceuticals, up from -$155.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$49.1 million in Q2 2024 to a low of -$155.0 million in Q4 2025.
• Historically, Enterprise Value has averaged -$84.7 million across 5 years, with a median of -$77.1 million in 2025.
• Biggest YoY gain for Enterprise Value was 53.42% in 2022; the steepest drop was 173.27% in 2022.
• A 5-year view of Enterprise Value shows it stood at -$58.2 million in 2022, then increased by 2.19% to -$56.9 million in 2023, then plunged by 35.81% to -$77.3 million in 2024, then tumbled by 100.4% to -$155.0 million in 2025, then increased by 5.34% to -$146.7 million in 2026.
• The last three Enterprise Value figures came in at -$146.7 million (Q1 2026), -$155.0 million (Q4 2025), and -$137.1 million (Q3 2025), per Business Quant data.